Mirati Therapeutics Inc (NASDAQ:MRTX) Director Aaron I. Davis sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $47.68, for a total transaction of $2,384,000.00. Following the completion of the transaction, the director now owns 70,409 shares in the company, valued at approximately $3,357,101.12. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of MRTX opened at $60.79 on Friday. Mirati Therapeutics Inc has a 12 month low of $21.50 and a 12 month high of $65.35. The firm has a market cap of $1.46 billion, a PE ratio of -21.87 and a beta of 1.49.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.85) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.02. Research analysts forecast that Mirati Therapeutics Inc will post -3.12 earnings per share for the current year.
MRTX has been the topic of several research reports. Cowen reiterated a “buy” rating on shares of Mirati Therapeutics in a research note on Monday, October 22nd. Oppenheimer set a $57.00 price objective on shares of Mirati Therapeutics and gave the company a “buy” rating in a research note on Sunday, November 11th. Zacks Investment Research upgraded shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, October 4th. Guggenheim upgraded shares of Mirati Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, October 29th. Finally, BidaskClub upgraded shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 5th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $54.89.
COPYRIGHT VIOLATION WARNING: “Aaron I. Davis Sells 50,000 Shares of Mirati Therapeutics Inc (MRTX) Stock” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.wkrb13.com/2019/01/11/aaron-i-davis-sells-50000-shares-of-mirati-therapeutics-inc-mrtx-stock.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.
Featured Article: How is inflation measured?
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.